ArticleJournal of molecular neuroscience : MN2026
High Mobility Group Box 1 contributes to Neuroinflammation and Central Sensitization After Nitroglycerin Stimulation in Mice.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this research was to clarify the effect of High Mobility Group Box 1 (HMGB1) in chronic migraine (CM).
methodsWe established a CM model by repeated intraperitoneal injection of nitroglycerin (NTG). Subsequently, Western blot was used to detect changes in HMGB1 protein expression at the trigeminal nucleus caudalis (TNC), and immunofluorescence was performed to determine HMGB1 intracellular localization. After model establishment, HMGB1 inhibitors Glycyrrhizin were administered intraperitoneally for 9 consecutive days. The paw withdrawal threshold (PWT) were measured using the electronic von Frey filament stimulation method. Additionally, changes in phosphorylated-ERK (p-ERK) and inducible nitric oxide synthase (iNOS) expression, as well as calcitonin gene-related peptide (CGRP) release levels at the TNC, were detected by WB and immunofluorescence staining.
resultsThe study revealed a significant increase of HMGB1 starting on day one, which peaked on day nine. Elevated levels remained significantly high for two weeks after NTG administration(p < 0.05). Additionally, HMGB1 was expressed in the nuclei of neurons, microglia and astrocytes. Behavioral assessments indicated a significant reduction in PWT from day five onward, indicative of mechanical hypersensitivity, which was alleviated following treatment with Glycyrrhizin(p < 0.05).The increased expression of p-ERK and iNOS, as well as the elevated levels of CGRP, were all significantly reduced following Glycyrrhizin treatment(p < 0.05).
conclusionsThese results show that HMGB1 plays a pivotal function in migraine by regulating neuroinflammation and central sensitization. Targeting HMGB1 may be able to mitigating chronic migraine.
Indexed as
Identifiers
42207345What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.